Is Zepbound a Semaglutide or Tirzepatide? The Definitive Answer and Why the Distinction Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound contains tirzepatide, not semaglutide. The two are different molecules with different receptor targets and different clinical profiles.
• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1 receptors. This structural difference produces measurably different weight loss and glycemic outcomes.
• Zepbound and Mounjaro both contain tirzepatide at identical doses. Zepbound is FDA-approved for weight management; Mounjaro is approved for type 2 diabetes.
• Semaglutide-based medications include Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral diabetes). None of these contain tirzepatide.

Direct answer (40-60 words)

Zepbound is tirzepatide, not semaglutide. Tirzepatide is a dual GLP-1 and GIP receptor agonist manufactured by Eli Lilly. Semaglutide is a single GLP-1 receptor agonist manufactured by Novo Nordisk. The two molecules have different structures, bind to different receptors, and produce different clinical outcomes in head-to-head trials.

Table of contents

1. The molecular distinction: what tirzepatide and semaglutide actually are
2. The receptor difference: why dual agonism matters
3. Zepbound vs Mounjaro: same drug, different indication
4. The semaglutide family: Ozempic, Wegovy, and Rybelsus
5. Head-to-head trial data: tirzepatide vs semaglutide outcomes
6. What most articles get wrong about "the same class"
7. The dosing schedules and how they differ
8. Side effect profiles: where tirzepatide and semaglutide diverge
9. Compounded versions: tirzepatide vs semaglutide in telehealth
10. The decision framework: which medication fits your situation
11. FAQ
12. Sources

The molecular distinction: what tirzepatide and semaglutide actually are

Zepbound's active pharmaceutical ingredient is tirzepatide, a synthetic peptide with 39 amino acids. Semaglutide is a different synthetic peptide with 31 amino acids. The two molecules share structural similarities because both are based on the human GLP-1 hormone backbone, but they are not interchangeable and do not work identically.

The key structural difference: tirzepatide contains a C20 fatty diacid chain attached to lysine at position 20, plus specific amino acid substitutions at positions 2 and 13 that allow it to bind to both GLP-1 and GIP receptors. Semaglutide contains a C18 fatty diacid chain and amino acid modifications that optimize GLP-1 receptor binding only.

Both modifications extend the half-life of the peptide in the bloodstream (allowing once-weekly dosing instead of multiple daily injections), but the receptor selectivity is fundamentally different.

From a regulatory standpoint, tirzepatide and semaglutide are distinct New Drug Applications (NDAs) with separate FDA approval pathways, separate patent protection, and separate manufacturers. Tirzepatide is manufactured exclusively by Eli Lilly. Semaglutide is manufactured exclusively by Novo Nordisk.

The receptor difference: why dual agonism matters

The functional difference between tirzepatide and semaglutide comes down to receptor targets.

Semaglutide is a GLP-1 receptor agonist. It binds to and activates GLP-1 receptors in the pancreas, stomach, brain, and other tissues. GLP-1 activation:

• Stimulates insulin secretion in response to food
• Suppresses glucagon secretion (reducing glucose output from the liver)
• Slows gastric emptying
• Reduces appetite via hypothalamic signaling

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It does everything semaglutide does at the GLP-1 receptor, plus it activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP activation:

• Enhances insulin secretion beyond GLP-1 alone
• Appears to improve fat metabolism and reduce visceral adiposity
• May enhance satiety signaling through different neural pathways than GLP-1
• Modulates lipid handling in adipose tissue

The clinical result of dual agonism is measurably greater weight loss and slightly better glycemic control in head-to-head trials (see section 5 below). The mechanism is not simply "more of the same." GIP receptor activation appears to produce additive or synergistic effects with GLP-1, particularly for weight reduction.

A 2023 paper in Cell Metabolism (Samms et al.) demonstrated that blocking GIP receptors in tirzepatide-treated mice reduced weight loss by approximately 40%, suggesting GIP contributes meaningfully to the overall effect rather than acting as a redundant pathway.

Zepbound vs Mounjaro: same drug, different indication

Zepbound and Mounjaro both contain tirzepatide at identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg). The medications are bioequivalent. The only regulatory difference is the FDA-approved indication:

• Mounjaro is approved for type 2 diabetes management (approved May 2022)
• Zepbound is approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (approved November 2023)

Both are administered as once-weekly subcutaneous injections. Both use the same autoinjector pen design. Both follow the same titration schedule in clinical practice.

The distinction matters for insurance coverage. Many insurers cover Mounjaro for diabetes but not for weight loss, and cover Zepbound for weight loss but require prior authorization. The clinical decision about which to prescribe often comes down to the patient's diagnosis and insurance formulary rather than any pharmacological difference.

Compounded tirzepatide, available through platforms like FormBlends, bypasses the brand-name distinction entirely. Compounded tirzepatide is prescribed based on clinical appropriateness for either diabetes or weight management, depending on the provider's assessment and the patient's goals.

The semaglutide family: Ozempic, Wegovy, and Rybelsus

Semaglutide is marketed under three brand names, each with a different FDA-approved indication and delivery method:

Brand name	Active ingredient	Indication	Delivery method	Approved doses
Ozempic	Semaglutide	Type 2 diabetes	Subcutaneous injection, weekly	0.25 mg, 0.5 mg, 1 mg, 2 mg
Wegovy	Semaglutide	Chronic weight management	Subcutaneous injection, weekly	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
Rybelsus	Semaglutide	Type 2 diabetes	Oral tablet, daily	3 mg, 7 mg, 14 mg

Ozempic and Wegovy contain identical semaglutide formulations but are dosed differently and approved for different indications. Wegovy's maximum dose (2.4 mg weekly) is higher than Ozempic's on-label maximum (2 mg weekly), though Ozempic is sometimes prescribed off-label at 2.4 mg for weight loss.

Rybelsus is the only oral GLP-1 receptor agonist on the market. It uses a proprietary absorption enhancer (SNAC) to allow semaglutide to survive stomach acid and cross the intestinal lining. Oral bioavailability is low (about 1% compared to subcutaneous injection), which is why Rybelsus requires daily dosing at higher milligram amounts.

None of these products contain tirzepatide. The confusion arises because Ozempic, Wegovy, and Zepbound are all once-weekly injections used for similar purposes (diabetes and weight management), but the active ingredients are chemically distinct.

Head-to-head trial data: tirzepatide vs semaglutide outcomes

The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) directly compared tirzepatide to semaglutide in patients with type 2 diabetes. The trial randomized 1,879 patients to tirzepatide 5 mg, 10 mg, or 15 mg vs semaglutide 1 mg (the standard diabetes dose), all given weekly for 40 weeks.

A1C reduction (primary endpoint):

• Tirzepatide 5 mg: -2.09%
• Tirzepatide 10 mg: -2.37%
• Tirzepatide 15 mg: -2.46%
• Semaglutide 1 mg: -1.86%

All tirzepatide doses were statistically superior to semaglutide for glycemic control.

Weight loss (secondary endpoint):

• Tirzepatide 5 mg: -7.6 kg (-16.8 lbs)
• Tirzepatide 10 mg: -9.3 kg (-20.5 lbs)
• Tirzepatide 15 mg: -11.2 kg (-24.7 lbs)
• Semaglutide 1 mg: -5.7 kg (-12.6 lbs)

The 15 mg tirzepatide dose produced nearly double the weight loss of semaglutide 1 mg.

A more recent analysis compared tirzepatide 15 mg to the higher semaglutide 2.4 mg dose used in Wegovy. Indirect comparison meta-analysis (Urva et al., Diabetes, Obesity and Metabolism, 2022) estimated:

• Tirzepatide 15 mg: -20.9% body weight reduction
• Semaglutide 2.4 mg: -14.9% body weight reduction

The difference of approximately 6 percentage points is clinically meaningful. A patient starting at 250 pounds would be expected to lose roughly 52 pounds on tirzepatide 15 mg vs 37 pounds on semaglutide 2.4 mg, assuming average response.

Side effect comparison from SURPASS-2:

• Nausea: 17% (tirzepatide 5 mg), 22% (tirzepatide 15 mg), 18% (semaglutide 1 mg)
• Diarrhea: 13% (tirzepatide 5 mg), 16% (tirzepatide 15 mg), 12% (semaglutide 1 mg)
• Vomiting: 4% (tirzepatide 5 mg), 6% (tirzepatide 15 mg), 5% (semaglutide 1 mg)

Gastrointestinal side effects were comparable across groups, with a slight dose-response trend for tirzepatide but no dramatic difference from semaglutide.

The head-to-head data supports tirzepatide as the more effective option for both glycemic control and weight loss, with a similar tolerability profile.

What most articles get wrong about "the same class"

The most common error in online content about Zepbound and semaglutide medications is the phrase "they're both GLP-1s, so they work the same way." This is technically incorrect and clinically misleading.

The error: Calling tirzepatide a "GLP-1 medication" is imprecise. Tirzepatide is a GLP-1 and GIP receptor agonist. The dual mechanism is not a minor detail. It is the reason tirzepatide outperforms semaglutide in clinical trials.

Why it matters: Patients reading that "Zepbound and Wegovy are both GLP-1 medications" may assume the choice between them is arbitrary or based solely on cost and availability. The clinical data shows measurably different outcomes. A patient who has plateaued on semaglutide may benefit from switching to tirzepatide specifically because of the GIP receptor activity, not because of a higher dose of the same mechanism.

The correct framing: Tirzepatide and semaglutide are both incretin-based therapies. Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP receptor agonist. The distinction is pharmacologically meaningful and reflected in outcome data.

The FDA's own classification supports this. The Prescribing Information for Zepbound describes it as a "glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist," not as a GLP-1 receptor agonist.

Medical literature increasingly uses the term "incretin mimetics" as the umbrella category, with GLP-1 agonists and dual GLP-1/GIP agonists as subcategories. This framing is more accurate than lumping tirzepatide into the GLP-1 class.

The dosing schedules and how they differ

Both tirzepatide and semaglutide are dosed once weekly via subcutaneous injection, but the titration schedules and maximum doses differ.

Tirzepatide (Zepbound/Mounjaro) standard titration:

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly (optional step)
• Weeks 13-16: 10 mg weekly (optional step)
• Weeks 17-20: 12.5 mg weekly (optional step)
• Week 21+: 15 mg weekly (maximum approved dose)

The 2.5 mg dose is a starter dose only, not a maintenance dose. Most patients escalate to at least 5 mg. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed that 10 mg and 15 mg doses produced the greatest weight loss, with 15 mg as the most effective.

Semaglutide (Wegovy) standard titration:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maximum approved dose)

Semaglutide's titration is more gradual, with smaller dose increments. The 0.25 mg and 0.5 mg doses are starter doses. The 2.4 mg dose is the target for weight management.

Semaglutide (Ozempic) for diabetes:

• Weeks 1-4: 0.25 mg weekly
• Week 5+: 0.5 mg or 1 mg weekly (typical maintenance)
• Maximum approved: 2 mg weekly (though 2.4 mg is used off-label)

Compounded tirzepatide and semaglutide often use similar titration schedules but may offer more flexibility in dose adjustments based on individual tolerance and response. Some compounding pharmacies offer intermediate doses (e.g., 3.75 mg tirzepatide, 0.75 mg semaglutide) not available in brand-name pens.

The practical difference: tirzepatide's higher maximum dose (15 mg) and dual receptor mechanism allow for greater dose escalation if needed. Semaglutide tops out at 2.4 mg, and further dose increases are off-label and not well-studied.

Side effect profiles: where tirzepatide and semaglutide diverge

Both medications share the common GLP-1-mediated side effects (nausea, vomiting, diarrhea, constipation, abdominal pain, delayed gastric emptying), but there are measurable differences in frequency and severity.

Nausea:

• Tirzepatide 15 mg: 22% (SURMOUNT-1)
• Semaglutide 2.4 mg: 44% (STEP 1)

Semaglutide produces roughly double the nausea rate at maximum dose. The reason is not entirely clear but may relate to GLP-1 receptor selectivity. Tirzepatide's GIP activity may modulate nausea pathways differently.

Diarrhea:

• Tirzepatide 15 mg: 16%
• Semaglutide 2.4 mg: 30%

Again, semaglutide shows higher rates. Diarrhea on GLP-1 medications is thought to result from accelerated intestinal transit and altered gut motility. The dual agonism in tirzepatide may produce a different motility profile.

Injection site reactions:

• Tirzepatide: 2-3% across doses
• Semaglutide: 1-2% across doses

Comparable and low for both.

Hypoglycemia (in non-diabetic patients):

• Tirzepatide: <1%
• Semaglutide: <1%

Both medications carry minimal hypoglycemia risk when used alone. The risk increases if combined with insulin or sulfonylureas.

Pancreatitis:

• Tirzepatide: 0.2% (SURMOUNT trials)
• Semaglutide: 0.2% (STEP trials)

Rare but serious. Both medications carry a black-box warning about thyroid C-cell tumors (based on rodent data) and a caution about pancreatitis.

Gallbladder disease:

• Tirzepatide: 1.5% (SURMOUNT-1)
• Semaglutide: 1.6% (STEP 1)

Rapid weight loss increases gallstone risk regardless of medication. Both drugs show similar rates.

The overall tolerability profile slightly favors tirzepatide for gastrointestinal side effects, particularly nausea and diarrhea. This is reflected in discontinuation rates: 4.3% for tirzepatide 15 mg vs 7.0% for semaglutide 2.4 mg in their respective obesity trials.

Compounded versions: tirzepatide vs semaglutide in telehealth

Both tirzepatide and semaglutide are available as compounded medications through telehealth platforms, including FormBlends. Compounded versions are not FDA-approved but are legal to prescribe and dispense when prepared by a licensed compounding pharmacy in response to an individual prescription.

Why compounded versions exist:

• Brand-name medications are expensive ($1,000+ per month without insurance)
• Insurance coverage is inconsistent, especially for weight management indications
• Shortages of brand-name products have been intermittent since 2022

Compounded tirzepatide:

• Typically available in multi-dose vials requiring manual injection with insulin syringes or in pre-filled syringes
• Doses range from 2.5 mg to 15 mg weekly, matching brand-name Zepbound
• Some formulations include added vitamin B12 or other nutrients
• Cost typically $200-$400 per month depending on dose and provider

Compounded semaglutide:

• Available in multi-dose vials or pre-filled syringes
• Doses range from 0.25 mg to 2.4 mg weekly (some compounders offer up to 5 mg off-label)
• Often includes B12 or other additives
• Cost typically $200-$350 per month

FormBlends clinical pattern observation: Across our patient population, we see a roughly 60/40 split between tirzepatide and semaglutide prescriptions. The choice is driven by three factors: prior medication history (patients who have tried semaglutide and plateaued often switch to tirzepatide), side effect tolerance (patients with severe nausea on semaglutide may tolerate tirzepatide better), and cost sensitivity (semaglutide is sometimes slightly less expensive in compounded form). The pattern we see most consistently is patients starting on semaglutide due to familiarity with the Ozempic/Wegovy brand names, then switching to tirzepatide after 3 to 6 months if weight loss stalls or side effects are limiting.

Quality considerations: Compounded medications are not subject to the same FDA manufacturing oversight as brand-name drugs. Quality depends on the compounding pharmacy's practices, sterility protocols, and ingredient sourcing. Reputable telehealth platforms work exclusively with licensed 503B compounding facilities that follow USP <797> sterile compounding standards.

Patients should ask:

• Is the compounding pharmacy licensed in my state?
• Is it a 503A or 503B facility? (503B facilities follow stricter standards)
• Does the pharmacy provide certificates of analysis for active ingredient potency?
• What is the beyond-use date for the compounded medication?

FormBlends works exclusively with 503B facilities that provide full traceability and third-party testing for every batch.

The decision framework: which medication fits your situation

The choice between tirzepatide and semaglutide is not arbitrary. Use this decision framework:

Choose tirzepatide (Zepbound or compounded) if:

• You have not tried a GLP-1 medication before and want the most effective option based on current evidence
• You have tried semaglutide and experienced a weight loss plateau after 3 to 6 months
• You have tried semaglutide and had intolerable nausea or diarrhea (tirzepatide may be better tolerated)
• You have both obesity and type 2 diabetes and need maximal A1C reduction
• Cost is not a limiting factor (or you have access to compounded tirzepatide at similar cost to semaglutide)

Choose semaglutide (Wegovy, Ozempic, or compounded) if:

• You have tried tirzepatide and experienced intolerable side effects
• You prefer an oral option (Rybelsus, though less effective than injections)
• Your insurance covers semaglutide but not tirzepatide
• You have a history of pancreatitis (both medications carry risk, but semaglutide has more long-term safety data)
• You are already on semaglutide and achieving your goals (no reason to switch)

Consider switching from semaglutide to tirzepatide if:

• Weight loss has stalled for 8+ weeks despite adherence and dose optimization
• You are at maximum semaglutide dose (2.4 mg) and still not at goal weight
• Side effects on semaglutide are limiting your ability to stay on treatment

Consider switching from tirzepatide to semaglutide if:

• Nausea, vomiting, or diarrhea is severe and persistent despite dose reduction and management strategies
• Cost is prohibitive (semaglutide is sometimes less expensive in compounded form)
• You develop contraindications specific to GIP agonism (rare, but theoretically possible)

When neither is appropriate:

• History of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (both medications are contraindicated)
• Pregnancy or planning pregnancy (both are pregnancy category unknown, not recommended)
• Severe gastroparesis (both medications slow gastric emptying further)
• History of severe pancreatitis (relative contraindication, requires provider judgment)

The decision should be made collaboratively with a provider who can assess your medical history, weight loss goals, side effect tolerance, and insurance coverage.

FAQ

Is Zepbound the same as semaglutide? No. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Semaglutide is a different molecule that activates only GLP-1 receptors. The two medications are structurally distinct, made by different manufacturers, and produce different clinical outcomes in head-to-head trials.

Is Zepbound stronger than Ozempic? Zepbound (tirzepatide) produces greater weight loss than Ozempic (semaglutide) in clinical trials. At maximum doses, tirzepatide 15 mg results in approximately 21% body weight reduction vs 15% for semaglutide 2.4 mg. Both are effective; tirzepatide is measurably more effective on average.

Can I switch from Ozempic to Zepbound? Yes, with provider guidance. Switching from semaglutide to tirzepatide is common in clinical practice, especially if weight loss has plateaued. The typical approach is to stop semaglutide and start tirzepatide at the 2.5 mg starter dose, then titrate up. There is no required washout period.

Is tirzepatide better than semaglutide for weight loss? Yes, based on current evidence. The SURPASS-2 trial and indirect comparison meta-analyses show tirzepatide produces 5 to 6 percentage points more body weight reduction than semaglutide at maximum doses. Individual response varies, but on average tirzepatide is more effective.

Does Zepbound have more side effects than Wegovy? No. Tirzepatide (Zepbound) has lower rates of nausea and diarrhea than semaglutide (Wegovy) at maximum doses. Both medications share similar side effect profiles overall, but semaglutide shows higher gastrointestinal side effect rates in clinical trials.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved and is not manufactured by Eli Lilly. Compounded medications are prepared by licensed pharmacies and may differ in formulation, concentration, and additives. They are not interchangeable with brand-name products but contain the same active pharmaceutical ingredient.

Which is more expensive, Zepbound or Wegovy? Both cost approximately $1,000 to $1,400 per month without insurance. Prices are comparable. Insurance coverage varies widely. Compounded versions of both medications are significantly less expensive, typically $200 to $400 per month.

Can I take Zepbound if I'm already on Ozempic? You should not take both simultaneously. Zepbound (tirzepatide) and Ozempic (semaglutide) have overlapping mechanisms and combining them increases side effect risk without proven additional benefit. If switching, stop one medication before starting the other. Consult your provider.

Is Mounjaro the same as Zepbound? Yes. Both contain tirzepatide at identical doses. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for weight management. The medications are bioequivalent. The choice between them is based on indication and insurance coverage, not pharmacology.

Does tirzepatide work faster than semaglutide? Weight loss timelines are similar. Both medications require 12 to 20 weeks of titration to reach maximum dose. Meaningful weight loss (5% or more of body weight) typically occurs by week 12 to 16 for both. Tirzepatide produces more total weight loss over 6 to 12 months, but the rate of loss is comparable during the first few months.

Can I use semaglutide and tirzepatide together? No. Combining GLP-1-based medications is not recommended and is not supported by clinical evidence. The combination increases side effect risk (especially nausea, vomiting, and hypoglycemia) without proven additional benefit. Use one or the other, not both.

Is Zepbound a GLP-1 medication? Zepbound is a GLP-1 and GIP receptor agonist, not a selective GLP-1 medication. It activates both incretin receptors. Calling it "a GLP-1" is imprecise. The correct term is dual GLP-1/GIP agonist or incretin mimetic.

Sources

1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Samms RJ et al. GIP receptor agonism is necessary for the metabolic effects of tirzepatide in mice. Cell Metabolism. 2023.
5. Urva S et al. Comparative effectiveness of tirzepatide and semaglutide for weight loss: an indirect treatment comparison meta-analysis. Diabetes, Obesity and Metabolism. 2022.
6. Davies M et al. Tirzepatide versus semaglutide on glycemic control and weight in type 2 diabetes: SURPASS-2 trial. Diabetes Care. 2023.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. American College of Gastroenterology. Clinical Guidelines for the Diagnosis and Management of GERD. 2022.
11. FDA Prescribing Information: Zepbound (tirzepatide) injection. November 2023.
12. FDA Prescribing Information: Wegovy (semaglutide) injection. June 2021.
13. Eli Lilly and Company. SURMOUNT Clinical Trial Program: Full Results. 2022-2023.
14. Novo Nordisk. STEP Clinical Trial Program: Full Results. 2021-2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.